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Over the past two years, there has been a dramatic rise in the prescription of lipid formulations of amphotericin B at our 
hospital. These compounds now account for a significant proportion of all expenditure on antimicrobial agents. We 
therefore conducted a review of the efficacy of the lipid formulations of amphotericin B. Only one randomized controlled 
trial has assessed the efficacy of any of these formulations in treating proven fungal infections, and this is only available 
in abstract form. Most of the available evidence on the use of lipid formulations is in  the form of case series. There are 
therefore limited data to justify the widespread use of these compounds, and we believe that there are few circumstances 
when their administration is warranted. We suggest that local policies should be drawn up for the prescription of lipid 
formulations of amphotericin 6, and, until more compelling data are available, that these drugs only be administered 
after discussion with microbiologists or infectious diseases physicians. 
I NTRODU CTI 0 N 
I’arenteral aniphotericin B in sodium deoxycholate 
(AniBDOC) has been the mainstay treatment for 
systemic fungal infection for the past thirty years. It has 
maintained its status as first-line therapy largely because 
of the lack of suitable alternatives; amphotericin B is far 
from being an ideal agent. Its use is associated with a 
number of unpleasant, and occasionally life-threaten- 
ing, infusion-related side effects, and, more importantly, 
it often causes renal impairment which may liniit the 
use of other medication (such as cyclosporin) and/or 
require dialysis. The need for less toxic and more 
effective antifungal compounds has led to the develop- 
nient of formulations of amphotericin B complexed 
with various forms of lipid [l]. A number of these 
compounds are now available, and we have witnessed a 
dramatic rise in their use within our hospital over the 
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past three years. These forinulations now account for 
15.5% of total spending on antimicrobial agents within 
our hospital (1995 figures) compared with less than 1 %  
three years ago, and we were concerned that this trend 
may be widespread at other centers. We therefore 
conducted a critical review of the evidence for the 
efficacy of these drugs, and suggest recommendations 
for their use. 
With a few notable exceptions, the field of clinical 
studies of antifungal therapy is notable for its lack of 
randomized, controlled trials. This situation has arisen 
because clinical trials in this area are difficult to 
conduct. Recruitment into studies niay be a problem, 
as the clinical and laboratory diagnosis of systemic 
mycosis is not easy; for instance, in a study by Mills 
et a1 [2], 20% of patients given a lipid formulation of 
amphotericin €3 therapy for fever unresponsive to 
antibiotics proved not to have disseminated fungal 
infection. However, in many patients the diagnosis of 
fungal infection is only established at postmortem [3]. 
Endpoints, such as ‘clinical response’ or ‘cure’, are 
difficult to define. This has resulted in a literature based 
largely on case reports, with most of the available 
comparative data relying on historical controls. Inter- 
preting such data can be misleading for a number of 
reasons. There may be substantial under-reporting of 
negative results and poor outcomes. Clinical remission 
niay be coincident with, but not the direct result of, a 
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change in antimicrobial therapy; for instance, recovery 
of the immune system of an affected individual may 
have been the crucial factor in recovery from fungal 
infection [4]. Furthermore, the use of historical controls 
can be unreliable because changes in the management 
of immunosuppressed patients (e.g. administration of 
colony-stimulating factors and/or prophylactic anti- 
microbials) other than the introduction of a new 
antifungal compound may occur during the study 
period. Case series composed of patients given ‘salvage 
therapy’, when a drug has been substituted for ampho- 
tericin B because of a perceived lack of efficacy or side 
effects, are also subject to bias. Individuals are often 
recruited into these studies only once they have failed 
to respond to a significant period on amphotericin B; 
thus a subset of patients who were going to recover 
anyway may be selected. Unfortunately, clinical ex- 
perience gained when using these compounds is 
unlikely to provide an accurate estimate of their efficacy 
because antifungals are most often prescribed on an 
empirical or ‘best guess’ basis, with only a proportion 
of those given treatment actually having a fungal 
infection. In these circumstances, the clinical impression 
of ‘response’ to a drug may lead to an overestimation of 
its true value. It is with these provisos in mind that we 
summarize the available data on the efficacy of lipid 
formulations of amphotericin B. 
FORMULATIONS AVAILABLE 
The lipid formulations of amphotericin B vary in their 
chemical compositions and pharmacokinetics, and it is 
important to regard each formulation as an entirely 
separate compound with its own properties; it is not 
possible to extrapolate data from one compound to 
another. All drugs in this category do, however, share 
a few common features; they are less toxic than 
AmBDOC, can be infused over a shorter time, and are 
more expensive than the parent compound. Table 3 
describes the formulations and lists their current costs 
to our hospital. 
Amphotericin B lipid complex (ABLC) (Abelcet-Liposome 
Company) 
Background 
Infusion of ABLC into mice leads to higher levels of 
amphotericin B in the liver and spleen than when 
animals are given equal doses of A d D O C  [S]; as in 
all other studies on the pharmacokinetics of anipho- 
tericin B, total amphotericin B was measured with no 
estimate of free or bound drug. Experiments in mice 
with disseminated fungal infections (e.g. candidosis, 
aspergillosis, cryptococcosis and histoplasmosis) sug- 
gested that AmBDOC is two to four times more 
effective than ABLC in a dose-for-dose comparison. 
However, as the LDso of ABLC in mice was more than 
an order of magnitude higher than that of the parent 
compound, ABLC has a higher therapeutic index than 
AmBDOC. 
ABLC was infused in doses of up to 0.5 mg/kg 
into eight healthy volunteers, and plasma levels of 
amphotericin B were lower than in a group given the 
same dose of the parent compound [6]. Infusion-related 
side effects were lower in the ABLC group, although 
transient elevations in serum transaminases were 
detected. I t  has been suggested that the large particle 
size of ABLC (1.6-11 pm) leads to its rapid clearance 
by reticuloendothelial cells, resulting in lower plasma 
levels. 
Table 1 Current lipid formulations of aniphotericin B 
Liposomal 
AnBDOC ABLC amphotericin B ABCD AmH-IL 
Conformation Micelles Sheets Unilainellar vesicles Disks Not known 
Diameter of particles (pm) 0.4 1.6-11 0.08 0.12 Not known 
Dosage (mg/kg/day) 0.5-1.0 5 3-5 Up to 6 0.5-1 .0 
Cost (A/lO0 mg) 7.40 86.00 390.00 199.00 16.00 
Costd (L/patient/day) 5.20 300 1380 836 13.80 
AmBDOC= amphotericin B a5 sodium deoxycholate complex (Fungizone-Squibb) 
ABLC=ainphotericin B lipid complex (Abelcet-Liposoine Company). 
Liposoinal aniphotericin €3 (AmBisonie-NeXstar). 
ABCD= amphotericin B colloidal dispersion (Aniphocil-Zeneca), 
AmB-IL=ainphotericin B in lipid emulsion (Intralipid-I’harmacia). 
“Calculated for a 70-kg person given the highest dose quoted. 
Note: The relativc costs of the drug? may be different for children, as ABLC is only available as a 100-ing vial. (Costs bated on the Brifislr 
,%tiorid Formulary, no. 31, March 1996.) 
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Clinical data 
Walsh et a1 [7,8] reported their experience of 228 
patients given ABLC (mean dose 4.9 ing/kg/day; range 
3.3-5.6) as salvage therapy for ‘presumed or confirmed’ 
systemic fungal infection. The majority of patients 
were entered because of failure to respond to con- 
ventional antifungal therapy (n = 134), with most of 
the remainder being enrolled because of AmBDOC 
nephrotoxicity; the study included 51 children. The 
underlying conditions were hematologic malignancy 
in 37% of individuals, solid tumors in 1496, organ 
transplant in 11%, and AIDS or other immune 
dysfunctions in 18%. Treatment was continued for a 
median duration of 25 days at a mean maxiinuni dose 
of 5 mg/kgday. There was no increase in serum 
creatinine during therapy with ABLC, although 20% of 
patients complained of fever or chills associated with 
the infusion. The response rate (i.e. coniplete or partial 
resolution of pretreatment clinical signs or symptoms) 
was 78% (52/67) for candidiasis and 60% (43/72) for 
aspergillosis, with equal rates observed in children and 
adults. These data were recently reviewed by Lister [91. 
A series of similar patients treated with ABLC was also 
presented by Lister [lo]. In this study, 47 individuals 
were changed from conventional antifungal therapy to 
ABLC, and clinical response was observed in 75% (cure 
in 33%), with a low incidence of renal impairment. 
Infusion-related events (mainly fever and chills) occur- 
red in 20‘%, of patients receiving ABLC salvage therapy. 
Recently, a study has been published in abstract 
form coinparing the efficacy of ABLC with that of 
AinBDOC for the treatment of imniunocompromised 
patients with definite or probable invasive aspergillosis 
using a historical control cohort [I I]. Indications for 
the prescription of ABLC were disease progression 
despite A n S D O C  or significant renal impairment. 
The clinical response rate in patients given ABLC was 
higher compared with historical controls (40% versus 
23%, p = 0.002). These data were used by the Food and 
Drugs Administration as evidence of efficacy in 
granting a licence for the use of ABLC in aspergillosis. 
Data coinparing ABLC and amphotericin B in a 
randomized, controlled fashion have been reported but 
are available in abstract form only. Anaissie et a1 [12] 
analyzed 231 patients randomized to receive ABLC 
(5 nig/kg; n= 153) or And3DOC (0.6-1 mg/kg; n=78) 
on an iiitentioii-to-treat basis in a multicenter study 
examining the treatinent of invasive candidiasis and 
fungemia. Only 30 patients were neutropenic a t  
the time of enrollment, arid 20% had an underlying 
hematologic malignancy as the underlying disease. 
The median duration of treatment with ABLC or 
AinBDOC was 14 days. Response rates (not defined) 
were not significantly different between the two groups 
(63% versus 68% for ABLC arid AmBDOC, respec- 
tively). However, the incidence of nephrotoxicity was 
higher in those receiving AmBDOC than in those 
receiving ABLC (doubling of serum creatinine, 47% 
versus 2896, respectively; p =  0.0;!8). These data indicate 
that ABLC is as effective as AmBDOC in treating 
patients with invasive candidosis. There are no con-  
parative studies in patients with invasive aspergillosis. 
Liposornal arnphotericin B (AmBisorne-NeXstar) 
Background 
High levels of amphotericin B are found in the 
liver and spleen of animals after infusion of liposonial 
amphotericin B, with variable amounts being present 
in the lung and kidney [ 131. The activity of liposomal 
amphotericin B in animal models of infection has been 
estimated to be either equivalent to or four to eight 
times less than that ofAml3DOC [14,15]. This has led 
to uncertainty about the optimum dosage of this drug 
in the clinical situation. The LDjo for this compound 
is high in mice, and therefore the therapeutic index 
for liposomal ainphotericin B is greater than that for 
AmBDOC [lh]. 
Clinical data 
No controlled trials have been conducted to define 
the efficacy of liposoiiial aniphotericin B for the treat- 
ment of fungal infections, although two studies have 
examined its role as a prophylactic agent for patients 
undergoing bone marrow or solid organ transplantation 
[ 17,181. There have, however, been several reports of 
the use of liposoinal amphotericin B as salvage therapy 
in inimunocompromised patienu following unsuccess- 
ful treatment with AmBDOC. Chopra et a1 1191 
described 40 patients with proven (9) or suspected (31) 
fungal infection. Seven of nine patients with proven, 
and 11 of the 31 with suspected, fungal infection 
responded to liposomal aniphotericin B. However, 
in 15 of the 18 patients who responded there was a 
concomitant improvement in immune function. 
Another study investigated the u!ie of liposomal ampho- 
tericin B as salvage therapy in 99 patients who had 
received at least 8 days of treatment with Aii1l31IOC 
(64 with proven, 24 with presumed and 11 with 
superficial infection) [20]; analysis of patients who had 
already survived 8 days is obviously a potential source 
of bias. Individuals were given Cl.5-5 mg/kg/day, with 
a mean duration of treatment of 26 days (range 8-97 
days), arid 58%) of the patients with proven infection 
(not defined) were cured. 
One  hundred and sixteeill hematology patients 
treated with liposomal ainphotericin B were described 
by Mills et a1 [2] .  The majority of patients ( n = Y Y )  
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enrolled had been given AmBDOC previously and had 
antibiotic-unresponsive fever with pulmonary involve- 
ment (81%). Subsequent results demonstrated that non- 
fungal pathogens were responsible for the illness in 20% 
of individuals in this series. The overall response rate to 
treatment was 56%, with 13 of the 17 patients with 
confirmed invasive aspergillosis improving on lipo- 
soma1 amphotericin B. Ng and Denning [21] reported 
the use of liposomal aniphotericin B on a coni- 
passionate release basis for 58 patients (30 with probable 
or definite invasive fungal infection). Doses of up to 
5 mg/kg were used, and the response rates for asper- 
gillosis and candidosis were 59% and 56% respectively. 
More recently, Kruger et a1 [22] described the use of 
liposomal amphotericin B in an open label study of 60 
patients with proven or suspected mycosis in the setting 
of bone marrow or stem cell transplantation. O f  the 50 
evaluable patients, 27 (60%) showed a clinical response 
(not defined) to treatment. The drug failed in six of 
seven patients with proven fungal infection. In all 
reports on liposomal amphotericin B, the incidence of 
renal impairment or infusion-related side effects is low 
(approximately 5% for both forms of adverse event). 
Amphotericin B in lipid emulsion (AmB-11) (lntralipid- 
Pharmacia) 
Background 
Little is known about the effect of mixing fat emulsions 
with amphotericin €3. A recent report [23] indicates 
that a significant proportion of amphotericin B pre- 
cipitates in 20% Intralipid; approximately 74 000 
particles/mL were found in a mixture of Intralipid 
and AmBDOC. The only published animal model 
examining the efficacy of this compound is in systemic 
candidosis of non-neutropenic mice [24]. The effect 
of treatment was assessed using a single bolus of 
drug given 48 h after intravenous challenge with 
Candida albicans. In this model, AmB-IL was equi- 
potent with AmBDOC and had a maximum tolerated 
dose 10-fold higher than that of the parent compound. 
Clinical data 
The safety of AmB-IL in neutropenic patients has been 
examined in three studies in which patients requiring 
empirical antifungal therapy were randomized to 
receive either AmBDOC or AmB-IL [25-271. Up to 
50 patients were included in the studies; AmB-IL was 
better tolerated than AmBDOC in all studies in terms 
of acute side effects and incidence of renal dysfunction 
(defined as a two-fold increase in serum creatinine in 
two reports, and as a 50% reduction in the creatinine 
clearance in the third). Data on the efficacy of AmB- 
IL are limited to two small studies. In the first, AnB- 
IL was compared with AmBDOC for the treatment of 
mucocutaneous candidosis in HIV-positive patients 
[28]. The compounds were equally effective, and fewer 
infusion-related side effects were noted in the AnB-IL 
group. The only report on the efficacy of AnB-IL 
in neutropenic patients was in 14 patients with candi- 
demia [29]. A d - I L  was used in all patients, 12 of 
whom also received flucytosine. Nine patients also had 
central venous catheters removed. Patients were entered 
if the same fungal species was isolated from two separate 
blood cultures. The dosage of A d - I L  was 1 nig/kg 
infused over 2-8 h. Ten of the patients responded; the 
only patient with fungal pneumonia died despite 
treatment. Because of the other interventions per- 
formed in these patients, the resolution of fungemia 
may not have resulted from administration of A d - I L .  
Suggestions for the use of this compound have been 
made recently [30]. 
Amphotericin B colloid dispersion (ABCD) 
(Amphocil-Zeneca) 
Background 
In experimental models, ABCD appears to be equally 
or slightly more efficacious than AmBDOC [31]; the 
models included candidosis, aspergillosis and crypto- 
coccosis. Doses of up to 1.5 mg/kg have been given to 
healthy volunteers [32]; there were mild side effects 
and no hepatic or renal impairment, and a preliminary 
report [33] suggested that doses of up to 7 mg/kg were 
well tolerated in patients with fungal infection. 
Clinical data 
In an open label study, ABLC was administered to 
168 patients at centers in Europe and the USA [34]. 
Individuals were included if they were judged to have 
not responded to 1 week of treatment with AmBDOC 
or had evidence of significant toxicity with this drug. 
ABCD was given in doses ranging from 0.5 mg/kg/day 
to 6mg/kg/day for a median duration of 12 days. 
Around 50% of the 97 clinically evaluable patients 
responded to treatment; patients were deemed un- 
evaluable if there was insufficient proof that they had a 
fungal infection (n=38), if they received <4  doses 
of ABCD (n=23), if they were also given itraconazole 
(n=4), and on the judgment of the investigator 
(n=6). Nineteen (58%) of 33 patients with candidosis 
responded. Of  those with invasive aspergillosis (32 
patients), a third responded on administration of 
ABCD. Only 8% of patients were withdrawn from 
the study because of adverse events, with 38% of 
individuals recording infusion-related fever during 
therapy. There was no overall net change in creatinine 
levels in patients receiving ABLC. 
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SPECIAL CIRCUMSTANCES 
Renal impairment 
In patients with stable, pre-existing renal disease, 
standard doses of AmBDOC should be given to treat 
systemic fungal infection. There is no evidence of 
AmBDOC accumulation in anephric patients [35]. Use 
of a lipid formulation should be considered as first-line 
therapy either if the renal function is deteriorating 
significantly or if the preservation of renal function is 
critical. Impairment of renal function during therapy 
appears to be less common with liposoinal ampho- 
tericin B than with ABLC (see above). 
Children 
There are limited data on the use of lipid formulations 
in children. Two reports describe the use of liposoiiial 
aniphotericin B in a total of 18 children with hernato- 
logic malignancies [36,37]. Therapy was well tolerated, 
with no infusion-related fever or chills reported. Data 
on the use of ABLC in children are limited; the report 
by Walsh et al [7] included 50 pediatric patients but 
these were not analyzed separately. 
DISCUSSION 
There is a general paucity of data on the clinical use 
of lipid-associated amphotericin B. Pressing clinical 
need has led to the introduction of a number of these 
compounds before full evaluation has been possible, 
and the choice between the compounds is niade diffi- 
cult because of the lack of reliable data. Sufficient 
inforniation exists showing unambiguously that ABLC, 
liposoiiial arriphotericin B and AmB-IL are less nephro- 
toxic than AnlBDOC, and all are associated with 
fewer infusion-related side effects, with these adverse 
reactions being less coninion with liposonial anipho- 
tericin B than the other formulations. 
Published data on the comparative efficacy of these 
drugs with each other and with the parent conipound 
are not, as yet, available. Concerns about the interaction 
between amphotericin B and Intralipid, together with 
the absence of information about the efficacy of this 
mixture, mean that the use of Am€-IL should be 
limited to clinical trials only. From preliminary data, 
AULC does appear to be as eifective as AmBDOC in 
treating patients with invasive candidosis but its role in 
the therapy of iiivasive aspergillosis is unclear. Although 
there are a nuniber of case series describing the use of 
liposonial aniphotericin B, there are no rigorous com- 
parative data on its efficacy in proven fungal infection. 
Therefore, we do not believe that the widespread use 
of lipid formulations of amphotericin B is justified, but 
rather that there are a limited number of situations 
when they should be considered. We suggest the 
following as the basis for rational use of these agents: 
Patients requiring systemic arnphotericin B should 
be given AmdDOC as first-line therapy, and only 
switched to a lipid formulation if there is either 
deteriorating renal function (doubling of serum 
creatinine over baseline), or jiilure of conventional 
AiilBDOC given at full dose (0.6-1 nig/kg/day). 
The use of lipid formulation as first-line therapy 
may be justified if there is rapidly deteriorating renal 
function or a renal allograft. 
We recommended that the use of these expensive and, 
as yet, unproven compounds needs careful monitoring, 
and that audit of their use, against agreed prescribing 
policy, is best carried out by pharmacy departments. 
These agents should only be administered following 
consultation between prescribers, microbiologists and 
infectious diseases physicians. Eiicuring that only appro- 
priate patients receive lipid formulations of arnpho- 
tericin B is a challenge facing all involved in providing 
care for iinmunocoiiipromised individuals. 
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